Sunifiram (DM-235)
Cognitive · Ampakine-like
Tier D
Bottom line
Read Off Label grades Sunifiram (DM-235) as D (3.3/10) based on preclinical only evidence, unclear benefit magnitude, and a unclear-risk safety profile.
No human trials.
Typical use: No established human dosing — Research chem; banned in some countries.
What this is
No human trials. Banned in Japan and possibly other jurisdictions. Sold as research chemical. AMPA PAM activity raises theoretical seizure risk with chronic use. Popular in early 2010s nootropic forums.
Mechanism
Piperazine derivative; positive allosteric modulator of AMPA receptors (similar effect to ampakines); claimed 1000x potency vs piracetam in mouse amnesia models
Dose & route
No established human dosing
Citations
- https://pubmed.ncbi.nlm.nih.gov/11964160/
- https://pubmed.ncbi.nlm.nih.gov/12499064/
- https://pubmed.ncbi.nlm.nih.gov/21777480/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Sunifiram (DM-235) work?
- Read Off Label rates the evidence for Sunifiram (DM-235) as Preclinical only and the benefit magnitude as unclear, producing an overall grade of D (3.3/10). No human trials.
- Is Sunifiram (DM-235) safe?
- Sunifiram (DM-235) has a unclear risk profile in published human data. Legal status: Research chem; banned in some countries. This is not medical advice — see the disclaimer.
- What is the typical dose for Sunifiram (DM-235)?
- No established human dosing
- How does Sunifiram (DM-235) work?
- Piperazine derivative; positive allosteric modulator of AMPA receptors (similar effect to ampakines); claimed 1000x potency vs piracetam in mouse amnesia models
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.